Figure 1.

Schema of the phase II dacarbazine trial. Baseline assessments included medical history, physical examination, vital signs, clinical laboratory tests including complete blood count and metabolic profile, and baseline imaging including CT and FDG-PET/CT (skull vertex to thighs), were performed within 21 days of cycle 1.